Showing 2681-2690 of 9124 results for "".
The Importance and Utility of GEP Testing
https://practicaldermatology.com/series/updates-in-skin-cancer/the-importance-and-utility-of-gep-testing/35597/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses gene expression profiling technology and its importance in the diagnosis and prognostication of melanomas.Making Hair Care Safer for Skin
https://practicaldermatology.com/series/c-suite-chats/making-hair-care-safer-for-skin/32711/Iris Rubin, Founder and Chief Medical Officer of SEEN, discusses how hair care products can cause a variety of skin issues, and the process in which she developed SEEN hair care.Cutaneous Oncology Update: Dr. Ruiz
https://reachmd.com/programs/practical-dermatology/cutaneous-oncology-update-dr-ruiz/32696/Emily Ruiz, MD, discusses the key points she covered about nonmelanoma skin cancer during "Cutaneous Oncology Update 2025" at Maui Derm 2025, as well as her poster presentation on the 40-GEP test for head and neck cutaneous squamous cell carcinomas.Combination Treatment: Dr. Shamban
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combination-treatment-dr-shamban/32685/Ava Shamban, MD, talks about the combination treatments—such as energy-based devices, peels, and laser-assisted drug delivery—that she covered in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025.Epidermal Inclusion Cysts: Dr. Goldman
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/epidermal-inclusion-cysts-dr-goldman/32687/Mitchel Goldman, MD, who took part in the "Neuromodulator and Dermal Filler" panel at Maui Derm 2025, talks about a new treatment for epidermal inclusion cysts, involving sclerotherapy medication.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Chronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.Actinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sExpanding Indications for Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/expanding-indications-for-neuromodulators-and-fillers-/18626/Emerging science of neuromodulators and fillers are expanding the role of these agents in dermatology practice, according to Dee Anna Glaser, MD. An intriguing area of research, she said, is the use of neuromodulators in the treatment of scars, as well as at the time of surgery for scar prevention.